TELA Bio, Inc. (NASDAQ:TELA) Q2 2022 Earnings Conference Call August 10, 2022 4:30 PM ET

Company Participants

Louisa Smith – Gilmartin Group

Tony Koblish – President and Chief Executive Officer

Roberto Cuca – Chief Operating Officer and Chief Financial Officer

Conference Call Participants

Frank Takkinen – Lake Street Capital Markets

Caitlin Cronin – Canaccord

Matthew O'Brien – Piper Sandler

Dave Turkaly – JMP Securities

Operator

Good afternoon, ladies and gentlemen, and welcome to the TELA Bio Second Quarter 2022 Earnings Conference Call. At this time all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. As a reminder, this conference is being recorded.

I would now like to turn the conference over to Louisa Smith from the Gilmartin Group. Please go ahead.

Louisa Smith

Thank you, Lue, and good afternoon everyone. Earlier today, TELA Bio released financial results for the second quarter of 2022. A copy of the press release is available on the company's website. Joining me on today's call are Tony Koblish, President and Chief Executive Officer; and Roberto Cuca, Chief Operating Officer and Chief Financial Officer.

Before we begin, I'd like to remind you that during this conference call, the company may make projections and forward-looking statements regarding future events. We encourage you to review the company's past and future filings with the SEC, including, without limitation, the company's 2021 Form 10-K and Form 10-Qs, which identify the specific factors that may cause actual results or events to differ materially from those described in these forward-looking statements. These factors may include, without limitation, statements regarding product development, product potential, the impact of COVID-19, the regulatory environment, sales and marketing strategies, capital resources or operating performance.

With that, I'll now turn the call over to Tony.

Tony Koblish

Thank you, Louisa. Good afternoon and thanks for joining us today on our second quarter 2022 earnings call. I am very pleased to report that TELA Bio achieved its first double-digit revenue quarter with net sales of $10.4 million, growing 38% year-over-year and 26% sequentially from the first quarter. On today's call, I'll describe how we plan to continue growing revenue and taking market share, update you on the progress of our sales force expansion, discuss the signing of the Premier contract and what that means for our business and review our latest clinical news. Then Roberto will provide a financial review of the quarter and I will make some closing comments before we take your questions.